How have GNRRF shares performed in 2024?

GeNeuro's stock was trading at $4.55 at the beginning of the year. Since then, GNRRF shares have increased by 0.0% and is now trading at $4.55. View the best growth stocks for 2024 here .

How do I buy shares of GeNeuro?

Shares of GNRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:GNRRF

GeNeuro (GNRRF) Stock Price, News & Analysis

→ Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad)

Free GNRRF Stock Alerts

$4.55

0.00 (0.00%)

(As of 02/17/2023)

Compare

Today's Range: $4.55
▼
$4.55
50-Day Range: $4.55
▼
$4.55
52-Week Range: $4.55
▼
$4.55

Volume: N/A
Average Volume: 4,633 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get GeNeuro alerts:

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About GeNeuro Stock (OTCMKTS:GNRRF)

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

GNRRF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNRRF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive GNRRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeNeuro and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:GNRRF
CUSIP: N/A
CIK: N/A
Web: www.geneuro.ch
Phone: 41 22 552 48 00
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Jesus Martin-Garcia (Age 61)
Chairman & CEO
Comp: $656.13k
Mr. Miguel Payró (Age 58)
Chief Financial Officer
Dr. Hervé Perron (Age 64)
Chief Scientific Officer
Dr. David Leppert M.D. (Age 65)
Chief Medical Officer
Dr. Alois B. Lang Ph.D. (Age 71)
Chief Devel. Officer

Key Competitors

View All Competitors

GNRRF Stock Analysis - Frequently Asked Questions

How have GNRRF shares performed in 2024?: GeNeuro's stock was trading at $4.55 at the beginning of the year. Since then, GNRRF shares have increased by 0.0% and is now trading at $4.55.
View the best growth stocks for 2024 here.
How do I buy shares of GeNeuro?: Shares of GNRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNRRF) was last updated on 5/8/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial